Dr. Daniel Peters discussed targeted therapies and regimens that patients with acute myeloid leukemia, or AML, should be aware of. During a recent visit to the Georgia Cancer Center, CURE sat down for ...

In a new trial, patients newly diagnosed with acute myeloid leukemia (AML) fared significantly better with a combined regimen of azacitidine and venetoclax compared with conventional induction ...

Acute myeloid leukemia (AML) afflicts older individuals (median age 68 years), the majority of whom are unfit to receive intensive induction chemotherapy. In November 2018, the FDA granted accelerated ...

The study included patients who received venetoclax treatment at Kyoto University Hospital and its collaborating institutions between June 2020 and July 2023 and who provided informed consent.

Venetoclax plus pediatric-inspired chemotherapy yielded an 87% post-induction response in adult T-ALL, with 75% MRD negativity among complete remissions and strong activity in ETP-ALL. Cytopenias were ...

The US Food and Drug Administration (FDA) has approved an oral form of azacitidine (Onureg) for use as maintenance therapy for patients with acute myeloid leukemia (AML) who have achieved a first ...

ORLANDO -- Azacitidine and venetoclax (Venclexta) significantly improved event-free survival (EFS) in newly diagnosed fit adults with acute myeloid leukemia (AML) compared with conventional induction ...

He also reviews the development of menin inhibitors in AML, including recent regulatory advances in the relapsed/refractory ...